ClinicalTrials.gov Search Results 09/25/2021
Title Status Study Results Conditions Interventions Locations 1 The Application of Impulse Oscillometry on the Diagnosis of Unknown status No Results Available •Asthma-COPD Overlap Syndrome •Diagnostic Test: Impulse Oscillometry •Shenjing Hospital, Shenyang, Liaoning, China ACOS,Asthma and COPD. •Asthma •COPD •Diagnoses Disease 2 The Study for Evaluating Factors Relating to Daily Step Completed No Results Available •Pulmonary Disease, Chronic Obstructive •Tohoku University School of Medicine, Sendai, Miyagi, Japan Counts and Physical Activity in Japanese Patients With COPD. 3 Prevention of Post-exercise Muscle Fatigue and Effect on Completed No Results Available •Obstructive Lung Diseases •Device: Inspiratory help then sham •CHU de Clermont-Ferrand, Clermont-ferrand, France Exercise Training in Severe Patients With COPD. ventilation •Clinique Cardio-pneumologique de Durtol, Durtol, France •Device: Sham ventilation then Inspiratory •CHU de Saint-Etienne, Saint-Etienne, France help 4 Discovering New Treatments for Asthma and COPD. A New Completed No Results Available •Rhinovirus •Other: Titre 1 Human Rhinvovirus for Human Challenge •Other: Titre 2 •Other: Titre 3 5 Airway Inflammation and Remodeling in Asthma and COPD. Completed No Results Available •Asthma •Department of Internal Medicine, Pneumonology and Allergology, Medical University of Warsaw 02-097, Warsaw, •COPD Poland 6 Impact of Hypnosis Intervention on the Emotional Dimension Recruiting No Results Available •Chronic Obstructive Pulmonary Disease •Other: Hypnosis intervention focused on •Clinique du Souffle la Vallonie, Lodève, France of Dyspnea in Patients With COPD. the emotional dimension of the dyspnea •Clinique du Souffle la Solane, Osséja, France 7 Tiotropium / Respimat One Year Study in COPD. Completed Has Results •Pulmonary Disease, Chronic Obstructive •Device: Respimat •205.372.01012 Boehringer Ingelheim Investigational Site, Birmingham, Alabama, United States •Drug: Tiotropium •205.372.01020 Boehringer Ingelheim Investigational Site, Birmingham, Alabama, United States •205.372.01062 Boehringer Ingelheim Investigational Site, Mobile, Alabama, United States •205.372.01048 Boehringer Ingelheim Investigational Site, Berkeley, California, United States •205.372.01037 Boehringer Ingelheim Investigational Site, Huntington Park, California, United States •205.372.01058 Boehringer Ingelheim Investigational Site, Long Beach, California, United States •205.372.01059 Boehringer Ingelheim Investigational Site, Long Beach, California, United States •205.372.01007 Boehringer Ingelheim Investigational Site, Los Angeles, California, United States •205.372.01034 Boehringer Ingelheim Investigational Site, Los Angeles, California, United States •205.372.01028 Boehringer Ingelheim Investigational Site, Rancho Mirage, California, United States •and 324 more 8 Acute Effects of Incremental Inspiratory Loads on Respiratory Unknown status No Results Available •Chronic Obstructive Pulmonary Disease •Procedure: incremental inspiratory load •Zhujiang Hospital,Southern Medical Universtiy, Guangzhou, Mechanics and NRD in Patient With Stable COPD. Guangdong, China 9 Effects of Different Modes of Respiratory MuscleTraining Unknown status No Results Available •Chronic Obstructive Pulmonary Disease •Device: inspiratory pressure threshold •Zhujiang Hospital,Southern Medical Universtiy, Guangzhou, on Respiratory Mechanics and NRD in Patient With Stable (COPD) device Guangdong, China COPD.
- Page 1 of 13 - Title Status Study Results Conditions Interventions Locations 10 Efficacy and Safety Study of Acetylcysteine/Doxofylline Completed No Results Available •COPD •Drug: Acetylcysteine/Doxofylline •Cukurova University Faculty of Medicine, Chest Diseases 1200/400 mg Effervescent Tablet in the Treatment of Department, Adana, Turkey •Other: Placebo Moderate-Severe COPD. •Health Sciences University, Sureyyapasa Chest Diseases and Thoracic Surgery Training and Research Hospital, Istanbul, Turkey 11 Study to Evaluate the Impact of the "PROactive Telecoaching Withdrawn No Results Available •COPD •Device: Automated telehealth system Program" on Physical Activity in Patients With COPD. •Other: Usual care 12 Efficacy and Safety of 4 Weeks Treatment With Inhaled BI Completed Has Results •Pulmonary Disease, Chronic Obstructive •Drug: BI 1744CL •1222.5.03 Boehringer Ingelheim Investigational Site, 1744 CL in Patients With COPD. Birmingham, Alabama, United States •Asthma •1222.5.07 Boehringer Ingelheim Investigational Site, Lakewood, California, United States •1222.5.14 Boehringer Ingelheim Investigational Site, Denver, Colorado, United States •1222.5.17 Boehringer Ingelheim Investigational Site, Wheat Ridge, Colorado, United States •1222.5.13 Boehringer Ingelheim Investigational Site, WheatRidge, Colorado, United States •1222.5.18 Boehringer Ingelheim Investigational Site, Stamford, Connecticut, United States •1222.5.15 Boehringer Ingelheim Investigational Site, Panama City, Florida, United States •1222.5.04 Boehringer Ingelheim Investigational Site, Coeur D'Alene, Idaho, United States •1222.5.22 Boehringer Ingelheim Investigational Site, Shreveport, Louisiana, United States •1222.5.11 Boehringer Ingelheim Investigational Site, Reno, Nevada, United States •and 32 more 13 A Study to Characterize Pharmacokinetics of Tiotropium + Completed Has Results •Pulmonary Disease, Chronic Obstructive •Drug: Tiotropium (high dose) + Olodaterol •1237.24.24001 Boehringer Ingelheim Investigational Site, Olodaterol Fixed-dose Combination in Japanese Patients With Toshima-ku, Tokyo, Japan •Drug: Tiotropium (low dose) + Olodaterol COPD. 14 Impact of Telemedicine in the Rate of Readmission for COPD. Completed No Results Available •COPD •Device: Group intervention •Jaime Corral Peñafiel, Cáceres, Spain Project CRONEX 3.0 •Other: health care system 15 Evaluation of Efficacy and Safety of Symbicort® as an add-on Completed Has Results •Chronic Obstructive Pulmonary Disease, •Drug: Symbicort (budesonide/formoterol •Research Site, Concord, New South Wales, Australia Treatment to Spiriva® in Patients With Severe COPD. COPD turbuhaler 320/9ug) •Research Site, Sydney, New South Wales, Australia •Drug: Spiriva (tiotropium bromide 18ug) •Research Site, Auchenflower, Queensland, Australia •Research Site, Carina Heights, Queensland, Australia •Research Site, North Mackay, Queensland, Australia •Research Site, Adelaide, South Australia, Australia •Research Site, Daw Park, South Australia, Australia •Research Site, Clayton, Victoria, Australia •Research Site, Malvern, Victoria, Australia •Research Site, Nedlands, Western Australia, Australia •and 83 more 16 Effects of HFOT on Exercise Performance in Patients With Completed No Results Available •Chronic Obstructive Pulmonary Disease •Combination Product: High-flow oxygen •National Center of Cardiology and Internal Medicine, Bishkek, COPD. A Randomized, Controlled Trial. therapy (HFOT) Kyrgyzstan •Combination Product: Low-flow oxygen therapy (LFOT)
- Page 2 of 13 - Title Status Study Results Conditions Interventions Locations 17 Randomized, Double-blind, Placebo-controlled, Multicenter, Completed Has Results •Chronic Obstructive Pulmonary Disease •Drug: QVA149 •Novartis Investigative Site, Koblenz, NRW, Germany Cross-over Study to Assess the Effects of a 3 Week Therapy •Drug: Placebo •Novartis Investigative Site, Cottbus, Sachsen, Germany Each With QVA149 Versus Placebo on Pulmonary Function and Average Physical Activity Levels in Patients With COPD. •Novartis Investigative Site, Geesthacht, Schleswig Holstein, Germany •Novartis Investigative Site, Aschaffenburg, Germany •Novartis Investigative Site, Berlin, Germany •Novartis Investigative Site, Berlin, Germany •Novartis Investigative Site, Berlin, Germany •Novartis Investigative Site, Dueren, Germany •Novartis Investigative Site, Erlangen, Germany •Novartis Investigative Site, Euskirchen, Germany •and 20 more 18 Role of A Disintegrin and Metalloproteinase (ADAM) in Completed No Results Available •Chronic Obstructive Pulmonary Disease Epithelial Dysfunction 19 Vitamin D as Treatment for Chronic Obstructive Pulmonary Completed No Results Available •Chronic Obstructive Pulmonary Disease •Drug: D-cure •Katholieke Universiteit Leuven, Leuven, Flanders, Belgium Disease (COPD) •Drug: Placebo •University hospital Leuven, Leuven, Flanders, Belgium 20 The Research of Metabolomics on COPD Completed No Results Available •Metabolomics •Diagnostic Test: Lung function test was performed on the subjects with Jaeger lung •Omega 6 function instrument of Germany. •Omega 3 •Diagnostic Test: Agilent 1290 Infinity LC •COPD system (UHPLC, Santa Clara CA) was used for Targeted metabolite detection. •Diagnostic Test: Routine blood test 21 Factors Influencing on Correctness of Inhalation Technique. Recruiting No Results Available •Asthma •Other: Assessment of correctness of •Department of Internal Medicine, Pneumonology and inhaling technique Allergology, Medical University of Warsaw, Warsaw, Poland •COPD 22 Appropriate Admission in COPD Exacerbation From Completed No Results Available •COPD Emergency Department. Multicenter Study 23 Complexity of the Airflow in COPD Unknown status No Results Available •COPD •Laboratório de Instrumentação Biomédica, Rio de Janeiro, Brazil 24 3 Minutes Chair Rise Test (3CRT) in Patients With COPD Completed No Results Available •Evaluations •Diagnostic Test: Chair Rise Tests and short •Centre Hospitalier Universitaire, Grenoble, France questionnaire •Rehabilitation •Hôpital Calmette, CHRU, Lille, France •COPD 25 Effects of Physical Activity Counseling After an Exacerbation Completed No Results Available •COPD Exacerbation •Behavioral: Physical activity •University Hospital Leuven, Leuven, Belgium in COPD 26 Tiotropium Respimat Versus HandiHaler on SaO2 and Sleep Completed Has Results •Chronic Obstructive Pulmonary Disease •Drug: tiotropium in COPD Patients •Device: Handihaler •Device: Respimat
- Page 3 of 13 - Title Status Study Results Conditions Interventions Locations 27 Dose Ranging Study of RPL554 in Chronic Obstructive Completed Has Results •COPD •Drug: RPL554 suspension •Clinic for pneumonology, Pleven, Bulgaria Pulmonary Disease (COPD) Patients •Drug: Placebo •SHATPPD-Ruse EOOD, Ruse, Bulgaria •Fifth MHAT - Sofia EAD, Sofia, Bulgaria •MHAT 'Lyulin', EAD, Sofia, Bulgaria •NMTH Tsar Boris III, Sofia, Bulgaria •UMHAT 'Alexandrovska' EAD, Sofia, Bulgaria •UMHAT 'Sveta Anna' AD, Sofia, Bulgaria •Medical Center Nov, Stara Zagora, Bulgaria •MediTrial s.r.o., Jind#ich#v Hradec, Czechia •Plicni stredisko Teplice, Teplice, Czechia •and 39 more 28 Respiratory Microbiome in COPD and Associated Inmune Unknown status No Results Available •Pulmonary Disease (COPD), Chronic •Oriol Sibila Vidal, Barcelona, Spain Response. Obstructive 29 The Efficacy and Safety of Salmeterol/Fluticasone Propionate Unknown status No Results Available •Chronic Obstructive Pulmonary Disease •Drug: Salmeterol/Fluticasone Propionate •Affiliated Hospital of Anhui Medical College, Hefei, Anhui, China vs Atropium/Albuterol in Patients COPD (COPD) •Beijing Chaoyang Hospital, Beijing, Beijing, China •Peking University Third Hospital, Beijing, Beijing, China •Gguang Zhou Institute of Respiratory Disease, Guangzhou, Guangdong, China •Henan Province Hospital, Zhengzhou, Henan, China •Jiangsu Province Hospital, Nanjing, Jiangsu, China •Wuxi People's Hospital,, Wuxi, Jiangsu, China •Shenyang Military General Hospital, Shenyang, Liaoning, China •Zhongshan Hospital, Shanghai, Shanghai, China •West China Hospital of Sichuan, Chendu, Sichuan, China •Chongqing Xinqiao Hospital, Chongqing, Sichuan, China 30 TRIMBOW® and RELVAR® on Lung Stiffness Reduction Not yet recruiting No Results Available •COPD •Drug: Beclometasone Dipropionate / Assessed Through Forced Oscillation Technique in Patients Formoterol Fumarate / Glycopyrronium With COPD 100/6/10 mcg •Drug: Fluticasone Furoate / Vilanterol Trifenatate 100/25 mcg 31 Research to Evaluate a Possible Relation Between Values Completed No Results Available •Pulmonary Disease, Chronic Obstructive •Radiation: Functional Respiratory Imaging •Antwerp University Hospital, Edegem, Antwerp, Belgium Obtained After Processing CT Images, Lung Function Tests •University of Florence, Florence, Italy and the Experience of the Patient During an Exacerbation in COPD Patients. •University Medical Center Groningen, Groningen, Netherlands •Maastricht University Medical Center, Maastricht, Netherlands 32 A Scintigraphy Study of PT010 in COPD Patients Completed No Results Available •Chronic Obstructive Pulmonary Disease •Drug: BGF-MDI •Research Site, Llanelli, United Kingdom •Research Site, Merthyr Tydfil, United Kingdom 33 Multidisciplinary Management of Severe COPD Recruiting No Results Available •Copd •Procedure: Multidisciplinary patient care •COPD-Center, Gothenburg, VGR, Sweden •COPD Exacerbation •Other: Standard care 34 Bronchodilators and Oxygen Kinetics With Exercise in Chronic Completed No Results Available •Chronic Obstructive Pulmonary Disease •Drug: Combivent •Respiratory Investigation Unit (Queen's University), Kingston, Obstructive Pulmonary Disease (COPD) Patients Ontario, Canada 35 Change in Breathing Pattern on Non-invasive Ventilation of Completed No Results Available •Copd •Other: Analysis of data from NIV built-in •Service de Pneumologie, Oncologie Thoracique et Soins COPD Patients Under Home Mechanical Ventilation software Intensifs Respiratoires, Rouen, Normandie, France •COPD Exacerbation
- Page 4 of 13 - Title Status Study Results Conditions Interventions Locations 36 Effects of Respiratory Muscle Training and Respiratory Unknown status No Results Available •Chronic Obstructive Pulmonary Disease •Other: Inspiratory muscle training •Federal University of Sao Carlos, Sao Carlos, Sao Paulo, Brazil Exercise in Exercise Tolerance, Performing Daily Life •Other: Respiratory exercise Activities and Quality of Life of Patients With Chronic Obstructive Pulmonary Disease 37 Comparative Effectiveness of Symbicort vs. Advair Among Completed No Results Available •COPD COPD Patients 38 The Effects of RPL554 on Top of Standard COPD Reliever Completed No Results Available •Chronic Obstructive Pulmonary Disease •Drug: Salbutamol •Medicines Evaluation Unit, Manchester, United Kingdom Medications •Drug: Ipratropium •Drug: RPL554 •Drug: Salbutamol matched placebo •Drug: Ipratropium matched placebo •Drug: RPL554 matched placebo 39 Beta Blocker Therapy in Moderate to Severe COPD Completed No Results Available •Chronic Obstructive Pulmonary Disease •Drug: Carvedilol •Asthma and Allergy Research Group, Ninewells Hospital and Medical School, University of Dundee, Dundee, United Kingdom •Drug: Bisoprolol •Drug: Beclometasone/formoterol •Drug: Tiotropium •Drug: Beclometasone 40 Estimation of the VQ11 Auto-questionnaire, to Follow Patients Completed No Results Available •COPD •Other: VQ11 validation •Clinique de l'Europe, Amiens, France With Chronic Obstructive Pulmonary Disease •CHU Amiens Nord, Amiens, France •CHU Amiens Sud, Amiens, France •Centre Hospitalier de Chauny, Chauny, France •Centre Hospitalier de Compiègne, Compiegne, France •Centre Médical, Compiegne, France •CH Creil, Creil, France •Centre Médical, Denain, France •CH de DOUAI, Douai, France •Hopital Jacques MONOD, Le Havre, France •and 7 more 41 Targeted Lung Denervation for Patients With Moderate to Unknown status No Results Available •Chronic Obstructive Pulmonary Disease •Device: Holaira™ Lung Denervation •AKH Allgemeines Krankenhaus der Stadt Linz GmbH, Linz, Severe COPD (COPD) System with energy delivery Austria •Device: Holaira™ Lung Denervation •Otto-Wagner-Spital, Vienna, Austria System without energy delivery •CHU Saint Pierre, Brussels, Belgium •University Hospital Leuven, Leuven, Belgium •CHU de Grenoble, Grenoble, France •CHU de Lille, Lille, France •CHU de Paris - Hopital Bichat Claude Bernard, Paris, France •CHU de Reims, Reims, France •CHU de Strasbourg, Strasbourg, France •Charite-Universitatsmedizin Berlin, Berlin, Germany •and 8 more 42 A Study to Assess the Effects of PT001 and PT005 MDI on Completed Has Results •COPD, Chronic Obstructive Pulmonary •Drug: GP MDI (PT001) 14.4 µg •Research Site, Edegem, Belgium Specific Image Based Parameters in Subjects With Moderate Disease •Drug: FF MDI (PT005) 9.6 µg •Research Site, Erpent, Belgium to Severe COPD
- Page 5 of 13 - Title Status Study Results Conditions Interventions Locations 43 Swiss studY for the Treatment of COPD Patients Completed Has Results •Chronic Obstructive Pulmonary Disease: •Drug: QAB149 •Novartis Investigative Site, Faltigberg-Wald, ZH, Switzerland With the Free combiNation of indacatERol and COPD •Drug: Placebo •Novartis Investigative Site, Barmelweid, Switzerland GlYcopyrroniumbromide. •Drug: NVA237 •Novartis Investigative Site, Basel, Switzerland •Novartis Investigative Site, Bern, Switzerland •Novartis Investigative Site, Bern, Switzerland •Novartis Investigative Site, Crans-Montana, Switzerland •Novartis Investigative Site, Lausanne, Switzerland •Novartis Investigative Site, Locarno, Switzerland •Novartis Investigative Site, Lugano, Switzerland •Novartis Investigative Site, St. Gallen, Switzerland •Novartis Investigative Site, Walenstadtberg, Switzerland 44 Efficacy, Pharmacokinetics (PK), Safety and Tolerability Study Completed Has Results •Chronic Obstructive Pulmonary Disease •Drug: AZD8871 100 µg •Research Site, Berlin, Germany of Inhaled AZD8871 COPD •Drug: AZD8871 600 µg •Research Site, Manchester, United Kingdom •Drug: Placebo 45 HandiHaler® vs. Metered Dose Inhaler (MDI) in Patients With Completed No Results Available •Pulmonary Disease, Chronic Obstructive •Device: Placebo capsule administered via Chronic Obstructive Pulmonary Disease (COPD) the HandiHaler® •Device: Ipratropium metered dose inhaler (MDI) 46 Regulation of the Release of Inflammatory Mediators From Withdrawn No Results Available •Chronic Obstructive Airway Disease •Procedure: Up to 100ml blood will be taken •National Heart & Lung Institute, Imperial College, Chelsea, Blood Leukocytes by venupuncture. London, United Kingdom •Healthy Volunteers 47 A Study to Evaluate Insulin in the Blood After Inhalation of Completed No Results Available •Chronic Obstructive Pulmonary Disease •Drug: Technosphere®/Insulin •Diabetes & Glandular Disease Research Assoc PA, San a Dry Powder Insulin Formulation (Called Technosphere®/ (COPD) Antonio, Texas, United States Insulin) in Non-diabetic Patients With & Without Chronic •Medical University Graz, Graz, Austria Obstructive Pulmonary Disease (COPD) •University Medical Centre Groningen, Zuidlaren, Netherlands •Medicines Evaluation Unit (MEU), Manchester, England, United Kingdom •ICON Development Solutions, Manchester, United Kingdom 48 Doxycycline and Airway Inflammation in Chronic Obstructive Unknown status No Results Available •Chronic Obstructive Pulmonary Disease •Drug: Doxycycline •Medical Center Alkmaar, Alkmaar, Noord-Holland, Netherlands Pulmonary Disease (COPD) •Inflammation •Drug: Placebo •Pulmonary Emphysema 49 Evaluation Of Patient Satisfaction Of Metered Dose Inhaler Completed No Results Available •Asthma •Drug: Fluticasone/Salmeterol HFA •GSK Investigational Site, Auchenflower, Queensland, Australia (MDI) With Counter In Asthmatics And Chronic Obstructive •GSK Investigational Site, Caboolture, Queensland, Australia Pulmonary Disease Patients (COPD). •GSK Investigational Site, Kippa Ring, Queensland, Australia •GSK Investigational Site, Perth, Western Australia, Australia
- Page 6 of 13 - Title Status Study Results Conditions Interventions Locations 50 Effect of Roflumilast on Exacerbation Rate in Patients With Completed Has Results •Chronic Obstructive Pulmonary Disease •Drug: Roflumilast •Altana Pharma/Nycomed Investigational Site, Fullerton, Chronic Obstructive Pulmonary Disease (COPD): The AURA (COPD) California, United States •Drug: Placebo Study (BY217/M2-124) •Altana Pharma/Nycomed Investigational Site, Los Angeles, California, United States •Altana Pharma/Nycomed Investigational Site, Los Angeles, California, United States •Altana Pharma/Nycomed Investigational Site, Palmdale, California, United States •Altana Pharma/Nycomed Investigational Site, Rancho Mirage, California, United States •Altana Pharma/Nycomed Investigational Site, San Diego, California, United States •Altana Pharma/Nycomed Investigational Site, Bay Pines, Florida, United States •Altana Pharma/Nycomed Investigational Site, Miami, Florida, United States •Altana Pharma/Nycomed Investigational Site, Panama City, Florida, United States •Altana Pharma/Nycomed Investigational Site, Atlanta, Georgia, United States •and 169 more 51 Effect of Roflumilast on Exacerbation Rate in Patients With Completed Has Results •Chronic Obstructive Pulmonary Disease •Drug: Roflumilast •Altana Pharma/Nycomed Investigational Site, Bayou La Batre, Chronic Obstructive Pulmonary Disease (COPD): The (COPD) Alabama, United States •Drug: Placebo HERMES Study (BY217/M2-125) •Altana Pharma/Nycomed Investigational Site, Birmingham, Alabama, United States •Altana Pharma/Nycomed Investigational Site, Birmingham, Alabama, United States •Altana Pharma/Nycomed Investigational Site, Huntsville, Alabama, United States •Altana Pharma/Nycomed Investigational Site, Bullhead City, Arizona, United States •Altana Pharma/Nycomed Investigational Site, Phoenix, Arizona, United States •Altana Pharma/Nycomed Investigational Site, Phoenix, Arizona, United States •Altana Pharma/Nycomed Investigational Site, Fort Smith, Arkansas, United States •Altana Pharma/Nycomed Investigational Site, Little Rock, Arkansas, United States •Altana Pharma/Nycomed Investigational Site, Anaheim, California, United States •and 277 more 52 Budesonide / Formoterol in Treatment of Exacerbations of Completed No Results Available •Chronic Obstructive Pulmonary Disease •Drug: budesonide/formoterol, 2x 200/6 •Research Site, Groningen, Netherlands COPD microgram. 4 times daily •Drug: prednisolone, 30 mg once daily and placebo 53 Telithromycin: in the Treatment of Acute Exacerbation of Completed No Results Available •Bronchitis, Chronic •Drug: Telithromycin Chronic Bronchitis in Adult Outpatients With COPD
- Page 7 of 13 - Title Status Study Results Conditions Interventions Locations 54 Vitamin D and Chronic Obstructive Lung Disease Withdrawn No Results Available •Chronic Obstructive Lung Disease •Dietary Supplement: Vitamin D (D3, •Hvidovre University Hospital, Department of Respiratory cholecalciferol) Medicine, Hvidovre, Denmark •Dietary Supplement: Placebo (cellulose) •Medical Unit, Hvidovre University Hospital, Hvidovre, Denmark 55 Tiotropium and Salmeterol PK Study in COPD Patients Completed No Results Available •Pulmonary Disease, Chronic Obstructive •Drug: Tiotropium+Salmeterol •1184.24.32001 Boehringer Ingelheim Investigational Site, Genk, Belgium •Drug: Salmeterol •1184.24.32002 Boehringer Ingelheim Investigational Site, •Drug: Tiotropium Hasselt, Belgium •1184.24.31001 Boehringer Ingelheim Investigational Site, Heerlen, Netherlands 56 A Study to Assess the Safety and Efficacy of Different AD 237 Completed No Results Available •COPD •Drug: AD 237 •Specialized Hospital for Active Treatment Pneumophthysiatric Doses in Adults With COPD Disease "Kudoglu", Plovdiv, Bulgaria •Regional Dispensary for Pulmonary Diseases Rousse, Rousse, Bulgaria •5-th Multiprofile Hospital for Active Treatment, Sofia, Bulgaria •MHAT "Alexandrovska", Sofia, Bulgaria •Specialized Hospital for Active Treatment of Pulmonary Diseases "Sveta Sofia", Sofia, Bulgaria •Central Clinical Base - Medical Institute - Ministry of the Interior, Sofia, Bulgaria •Military Medical Academy, Sofia, Bulgaria •UMHAT "Stara Zagora" EAD, Stara Zagora, Bulgaria •University Hospital, Varna, Bulgaria •Tudogyintezete Nodradgardony, Balassagyarmat, Hungary •and 23 more 57 Influence Of Salmeterol Xinafoate/Fluticasone Propionate Completed Has Results •Pulmonary Disease, Chronic Obstructive •Drug: Salmeterol / Fluticasone (50/500 µg) •GSK Investigational Site, Bruchsal, Baden-Wuerttemberg, (50/500 µg BID) On The Course Of The Disease And BID fixed combination Germany Exacerbation Frequency In COPD Patients Gold Stage III And •Drug: Salmeterol / Fluticasone (50/500 µg) •GSK Investigational Site, Heidelberg, Baden-Wuerttemberg, IV BID separate Inhalers Germany •GSK Investigational Site, Mannheim, Baden-Wuerttemberg, Germany •GSK Investigational Site, Wiesloch, Baden-Wuerttemberg, Germany •GSK Investigational Site, Cottbus, Brandenburg, Germany •GSK Investigational Site, Neuruppin, Brandenburg, Germany •GSK Investigational Site, Potsdam, Brandenburg, Germany •GSK Investigational Site, Eschwege, Hessen, Germany •GSK Investigational Site, Gelnhausen, Hessen, Germany •GSK Investigational Site, Kassel, Hessen, Germany •and 13 more 58 Risk of Re-Hospitalization in Patients With Chronic Completed No Results Available •Pulmonary Disease, Chronic Obstructive •Drug: FSC Obstructive Pulmonary Disease (COPD) Post Exacerbation •Drug: ACs 59 Analyzing Lung Tissue in People With and Without Chronic Completed No Results Available •Pulmonary Disease, Chronic Obstructive •Other: There is no intervention. Study is •Washington University School of Medicine, Saint Louis, Obstructive Pulmonary Disease Who Are Undergoing Lung observational. Missouri, United States Transplantation
- Page 8 of 13 - Title Status Study Results Conditions Interventions Locations 60 Efficacy and Safety of the Addition of Fluticasone Propionate/ Completed Has Results •Pulmonary Disease, Chronic Obstructive •Drug: Umeclidinium bromide 62.5mcg •GSK Investigational Site, Mobile, Alabama, United States Salmeterol (250/50mcg) Twice-daily to 2 Doses of •Drug: Umeclidinium bromide 125mcg •GSK Investigational Site, Phoenix, Arizona, United States Umeclidinium Bromide Inhalation Powder (62.5 or 125mcg) Once-daily Over 12 Weeks. •Drug: Fluticasone propionate 250mcg/ •GSK Investigational Site, Huntington Beach, California, United Salmeterol 50mcg States •GSK Investigational Site, DeLand, Florida, United States •GSK Investigational Site, Orlando, Florida, United States •GSK Investigational Site, Tampa, Florida, United States •GSK Investigational Site, Coeur D'Alene, Idaho, United States •GSK Investigational Site, Sunset, Louisiana, United States •GSK Investigational Site, St. Charles, Missouri, United States •GSK Investigational Site, Charlotte, North Carolina, United States •and 45 more 61 Factors That Affect the Development of COPD Symptoms Completed No Results Available •Pulmonary Disease, Chronic Obstructive •Washington University School of Medicine, Saint Louis, Missouri, United States 62 Indacaterol Delivered Via a Single Dose Dry Powder Inhaler Completed No Results Available •Pulmonary Disease, Chronic Obstructive •Drug: indacaterol maleate •Novartis, Vilvoorde, Belgium (SDDPI) in Chronic Obstructive Pulmonary Disease (COPD) •COPD •Lung Diseases, Obstructive 63 European Non-interventional Study in Chronic Obstructive Completed No Results Available •Chronic Obstructive Pulmonary Disease •Research Site, Baden, Austria Pulmonary Disease (COPD) Patients (COPD) •Research Site, Feldbach, Austria •Research Site, Feldkirch, Austria •Research Site, Gussing, Austria •Research Site, Innsbruck, Austria •Research Site, Landeck, Austria •Research Site, Linz-Urfahr, Austria •Research Site, Linz, Austria •Research Site, Neusiedl am See, Austria •Research Site, Salzburg, Austria •and 596 more 64 Home-based Treatment of Patients With Chronic Obstructive Completed No Results Available •COPD •Behavioral: closer collaboration between •Dept. of Lung Diseases, St.Olavs Hospital, Trondheim, Norway Pulmonary Disease (COPD) hospital and primary healthcare system •Behavioral: usual care
- Page 9 of 13 - Title Status Study Results Conditions Interventions Locations 65 Efficacy and Safety Comparison of Steroid or Placebo in Completed No Results Available •Pulmonary Disease, Chronic Obstructive •Drug: Tiotropium •1249.1.32003 Boehringer Ingelheim Investigational Site, Genk, Combination With Salmeterol and Tiotropium in COPD Belgium •Drug: Salmeterol •1249.1.32001 Boehringer Ingelheim Investigational Site, Gent, •Drug: Fluticasone Belgium •Drug: Ciclesonide low •1249.1.32002 Boehringer Ingelheim Investigational Site, •Drug: Ciclesonide high Hasselt, Belgium •Drug: Placebo •1249.1.32004 Boehringer Ingelheim Investigational Site, Oostende, Belgium •1249.1.45001 Boehringer Ingelheim Investigational Site, Aarhus C, Denmark •1249.1.49001 Boehringer Ingelheim Investigational Site, Großhansdorf, Germany •1249.1.49002 Boehringer Ingelheim Investigational Site, Mannheim, Germany •1249.1.49003 Boehringer Ingelheim Investigational Site, Weinheim, Germany •1249.1.31002 Boehringer Ingelheim Investigational Site, Eindhoven, Netherlands •1249.1.31003 Boehringer Ingelheim Investigational Site, Harderwijk, Netherlands •1249.1.31001 Boehringer Ingelheim Investigational Site, Heerlen, Netherlands •1249.1.31004 Boehringer Ingelheim Investigational Site, Veldhoven, Netherlands 66 Modification Of Disease Outcome In COPD Terminated No Results Available •Chronic Obstructive Pulmonary Disease •Drug: fluticasone 500 mcg •University Medical Center Groningen, Groningen, Netherlands •Drug: fluticasone 500 mcg + salmeterol 50 •Leiden University Medical Center, Leiden, Netherlands mcg 67 A Chronic Obstructive Pulmonary Disease (COPD) Trial Completed Has Results •COPD •Drug: Roflumilast •Beijing, China Investigating Roflumilast on Safety and Effectiveness in •Drug: Placebo •Changsha, China China, Hong Kong and Singapore: •Drug: Salbutamol •Chengdu, China •Chongqing, China •Fuzhou, China •Guangzhou, China •Hangzhou, China •Nanjing, China •Nanning, China •Qingdao, China •and 5 more 68 Antibiotics in Chronic Obstructive Pulmonary Disease (COPD) Withdrawn No Results Available •Pulmonary Disease, Chronic Obstructive •Drug: Doxycycline •Odense University Hospital, Odense, Denmark •Drug: Placebo (matching)
- Page 10 of 13 - Title Status Study Results Conditions Interventions Locations 69 Comparing the Efficacy of Tiotropium + Olodaterol (5/5 µg) Completed Has Results •Pulmonary Disease, Chronic Obstructive •Drug: olodaterol •1237.19.10039 Boehringer Ingelheim Investigational Site, Fixed Dose Combination (FDC) Over Tiotropium 5µg in Andalusia, Alabama, United States •Drug: tiotropium Reducing Moderate to Severe Exacerbations in Patients •1237.19.10009 Boehringer Ingelheim Investigational Site, With Severe to Very Severe Chronic Obstructive Pulmonary Birmingham, Alabama, United States Disease. •1237.19.10077 Boehringer Ingelheim Investigational Site, Florence, Alabama, United States •1237.19.10115 Boehringer Ingelheim Investigational Site, Jasper, Alabama, United States •1237.19.10069 Boehringer Ingelheim Investigational Site, Flagstaff, Arizona, United States •1237.19.10085 Boehringer Ingelheim Investigational Site, Peoria, Arizona, United States •1237.19.10110 Boehringer Ingelheim Investigational Site, Lincoln, California, United States •1237.19.10118 Boehringer Ingelheim Investigational Site, Los Angeles, California, United States •1237.19.10074 Boehringer Ingelheim Investigational Site, Poway, California, United States •1237.19.10157 Boehringer Ingelheim Investigational Site, Lafayette, Colorado, United States •and 808 more 70 QVA vs. Salmeterol/Fluticasone, 52-week Exacerbation Study, Completed Has Results •Chronic Obstructive Pulmonary Disease •Drug: QVA149 •Novartis Investigative Site, Caba, Buenos Aires, Argentina FLAME (EFfect of Indacaterol Glycopyronium Vs Fluticasone (COPD) •Drug: Long acting B2 agonist (LABA) and •Novartis Investigative Site, Caba, Buenos Aires, Argentina Salmeterol on COPD Exacerbations) inhaled corticosteroid (ICS) •Novartis Investigative Site, Caba, Buenos Aires, Argentina •Novartis Investigative Site, Caba, Buenos Aires, Argentina •Novartis Investigative Site, Caba, Buenos Aires, Argentina •Novartis Investigative Site, Caba, Buenos Aires, Argentina •Novartis Investigative Site, Caba, Buenos Aires, Argentina •Novartis Investigative Site, Caba, Buenos Aires, Argentina •Novartis Investigative Site, Lanus, Buenos Aires, Argentina •Novartis Investigative Site, Mar del Plata, Buenos Aires, Argentina •and 486 more 71 Enhancement of in-Vitro GC Function in Patients With COPD Completed Has Results •COPD •Drug: Fluticasone Propionate •Windsor chest clinic KEVII Hospital, Windsor, Berks, United Kingdom •Drug: placebo •Drug: Theophylline 72 Effects Of Oral Prednisolone On Bone Metabolism In Patients Completed No Results Available •Chronic Obstructive Pulmonary Disease •Drug: prednisolone •GSK Clinical Trials Call Centre, Cambridge, United Kingdom With Chronic Obstructive Pulmonary Disease
- Page 11 of 13 - Title Status Study Results Conditions Interventions Locations 73 Spiriva® Assessment of FEV1 (SAFE) Completed No Results Available •Pulmonary Disease, Chronic Obstructive •Drug: Tiotropium (Spiriva®) •Respiratory Research, Room 1742, Calgary, Alberta, Canada •Boehringer Ingelheim Investigational Site, Calgary, Alberta, Canada •4A-185, 7007-14 Street SW, Calgary, Alberta, Canada •Boehringer Ingelheim Investigational Site, Edmonton, Alberta, Canada •Boehringer Ingelheim Investigational Site, Lethbridge, Alberta, Canada •Boehringer Ingelheim Investigational Site, Medicine Hat, Alberta, Canada •301-131 First Ave., Spruce Grove, Alberta, Canada •Boehringer Ingelheim Investigational Site, Wetaskiwin, Alberta, Canada •Boehringer Ingelheim Investigational Site, Abbotsford, British Columbia, Canada •Boehringer Ingelheim Investigational Site, Chilliwack, British Columbia, Canada •and 86 more 74 Spiriva (Tiotropium Bromide) Assessment of FEV1 - (SAFE- Completed No Results Available •Pulmonary Disease, Chronic Obstructive •Device: Pulmonary function Testing •Hospital Garcia de Orta, Almada, Portugal Portugal). •Drug: tiotropium bromide •Hospital Fernando Fonseca, Amadora, Portugal •Hospital Santo Espírito de Angra do Heroismo, Angra do Heroismo - Açores, Portugal •Hospital Infante D. Pedro, Aveiro, Portugal •Unidade Funcional de Infecciologia, Barreiro, Portugal •Hospital de S. Marcos, Braga, Portugal •Hospitais da Universidade de Coimbra, Coimbra, Portugal •Centro Hospitalar de Coimbra, Coimbra, Portugal •Centro Hospitalar da Cova da Beira, Covilhã, Portugal •Hospital Distrital de Faro, Faro, Portugal •and 23 more 75 Measure of the Long Term Influence of SPIRIVA® in Acute Completed No Results Available •Pulmonary Disease, Chronic Obstructive •Drug: Tiotropium •Clinique Saint Sauveur, Angers, France Respiratory Disorders •Boehringer Ingelheim Investigational Site, Annecy, France •Clinique la Casamance, Aubagne, France •Boehringer Ingelheim Investigational Site, Avrille, France •Hôpital, Bois Guillaume cedex, France •GPL, Caluire, France •CH Cholet, Cholet, France •Boehringer Ingelheim Investigational Site, Cholet, France •Boehringer Ingelheim Investigational Site, Châlons en Champagne, France •Hôpital Gabriel Montpied, Clermont-Ferrand cedex 1, France •and 45 more 76 Urban Walking Circuits Completed No Results Available •Severe Chronic Obstructive Pulmonary •Other: rehabilitation more the urban circuit •Eulogio Pleguezuelos, Mataro, Barcelona, Spain Disease •Other: rehabilitation program but not given urbane circuits
- Page 12 of 13 - Title Status Study Results Conditions Interventions Locations 77 Symbicort in Chronic Obstructive Pulmonary Disease Completed No Results Available •Chronic Obstructive Pulmonary Disease 78 Symbicort in Chronic Obstruktive Pulmonary Disease Completed No Results Available •Pulmonary Disease, Chronic Obstructive 79 A 2 Part Study Examining Doses Of GSK961081 In Healthy Completed No Results Available •Pulmonary Disease, Chronic Obstructive •Drug: GSK961081 •GSK Investigational Site, Mainz, Rheinland-Pfalz, Germany Volunteers And Then In COPD Patients •GSK Investigational Site, Berlin, Germany •GSK Investigational Site, Bloemfontein, South Africa •GSK Investigational Site, George, South Africa •GSK Investigational Site, Mowbray, South Africa 80 Pursed-lips Breathing and Dynamic Hyperinflation Completed No Results Available •Chronic Obstructive Pulmonary Disease •Other: Pursed-lips breathing •Núcleo de Aisstência, Ensino e Pesquisa em Reabilitação Pulmonar, Florianópolis, Santa Catarina, Brazil •Other: No pursed-lips breathing
U.S. National Library of Medicine | U.S. National Institutes of Health | U.S. Department of Health & Human Services
- Page 13 of 13 -